Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Omeros shares jumped threefold to $12.32 in premarket trading. As part of the agreement, Novo gains exclusive global rights ...

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment.

The Turbo Trail Cruiser Concept maintains vintage Land Cruiser FJ60 vibes by modernizing the engine without sacrificing the ...

Ripple’s $1.25B Hidden Road deal positions Ripple Prime as a new force connecting digital assets and global finance.

Six thousand hens range under the solar array on 16ha (40 acres) of former arable land let to egg producers Charlie and Laura ...

L3Harris Technologies ( NYSE: LHX) on Monday said it was awarded a contract valued at more than $2.26 billion to deliver ...

Emperor Cleon is a very different beast in Foundation compared to the version depicted in Isaac Asimov's source material for ...